Literature DB >> 19876942

Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer.

Chuan-Hsiang Huang1, Sandra B Gabelli, Eric Oldfield, L Mario Amzel.   

Abstract

Bisphosphonates (BPs) are a class of compounds that have been used extensively in the treatment of osteoporosis and malignancy-related hypercalcemia. Some of these compounds act through inhibition of farnesyl diphosphate synthase (FPPS), a key enzyme in the synthesis of isoprenoids. Recently, nitrogen-containing bisphosphonates (N-BPs) used in bone resorption therapy have been shown to be active against Trypanosoma cruzi, the parasite that causes American trypanosomiasis (Chagas disease), suggesting that they may be used as anti-trypanosomal agents. The crystal structures of TcFPPS in complex with substrate (isopentenyl diphosphate, IPP) and five N-BP inhibitors show that the C-1 hydroxyl and the nitrogen-containing groups of the inhibitors alter the binding of IPP and the conformation of two TcFPPS residues, Tyr94 and Gln167. Isothermal titration calorimetry experiments suggest that binding of the first N-BPs to the homodimeric TcFPPS changes the binding properties of the second site. This mechanism of binding of N-BPs to TcFPPS is different to that reported for the binding of the same compounds to human FPPS. Proteins 2010. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19876942      PMCID: PMC3018326          DOI: 10.1002/prot.22614

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  19 in total

Review 1.  Bisphosphonates: pharmacology, mechanisms of action and clinical uses.

Authors:  R G Russell; P I Croucher; M J Rogers
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Intersubunit location of the active site of farnesyl diphosphate synthase: reconstruction of active enzymes by hybrid-type heteromeric dimers of site-directed mutants.

Authors:  T Koyama; Y Gotoh; T Nishino
Journal:  Biochemistry       Date:  2000-01-18       Impact factor: 3.162

Review 3.  Specific chemotherapy of Chagas disease: controversies and advances.

Authors:  Julio A Urbina; Roberto Docampo
Journal:  Trends Parasitol       Date:  2003-11

4.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

5.  Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.

Authors:  M B Martin; J S Grimley; J C Lewis; H T Heath; B N Bailey; H Kendrick; V Yardley; A Caldera; R Lira; J A Urbina; S N Moreno; R Docampo; S L Croft; E Oldfield
Journal:  J Med Chem       Date:  2001-03-15       Impact factor: 7.446

Review 6.  Farnesyl diphosphate synthase; regulation of product specificity.

Authors:  Anna Szkopińska; Danuta Płochocka
Journal:  Acta Biochim Pol       Date:  2005       Impact factor: 2.149

7.  Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis.

Authors:  David J Hosfield; Yanming Zhang; Douglas R Dougan; Alexei Broun; Leslie W Tari; Ronald V Swanson; John Finn
Journal:  J Biol Chem       Date:  2003-12-12       Impact factor: 5.157

Review 8.  New insights into the molecular mechanisms of action of bisphosphonates.

Authors:  Michael J Rogers
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi.

Authors:  Luciana R Garzoni; Aura Caldera; Maria de Nazareth L Meirelles; Solange L de Castro; Roberto Docampo; Gary A Meints; Eric Oldfield; Julio A Urbina
Journal:  Int J Antimicrob Agents       Date:  2004-03       Impact factor: 5.283

10.  Antiparasitic activity of risedronate in a murine model of acute Chagas' disease.

Authors:  Luciana R Garzoni; Mariana C Waghabi; Marcos M Baptista; Solange L de Castro; Maria de Nazareth L Meirelles; Constança C Britto; Roberto Docampo; Eric Oldfield; Julio A Urbina
Journal:  Int J Antimicrob Agents       Date:  2004-03       Impact factor: 5.283

View more
  17 in total

1.  Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.

Authors:  Valeria S Rosso; Sergio H Szajnman; Leena Malayil; Melina Galizzi; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Bioorg Med Chem       Date:  2011-04-01       Impact factor: 3.641

2.  1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase.

Authors:  Sergio H Szajnman; Valeria S Rosso; Leena Malayil; Alyssa Smith; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Org Biomol Chem       Date:  2012-01-03       Impact factor: 3.876

3.  Design, synthesis, calorimetry, and crystallographic analysis of 2-alkylaminoethyl-1,1-bisphosphonates as inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase.

Authors:  Srinivas Aripirala; Sergio H Szajnman; Jean Jakoncic; Juan B Rodriguez; Roberto Docampo; Sandra B Gabelli; L Mario Amzel
Journal:  J Med Chem       Date:  2012-07-05       Impact factor: 7.446

Review 4.  Advances in Chagas disease drug development: 2009-2010.

Authors:  Frederick S Buckner; Nazlee Navabi
Journal:  Curr Opin Infect Dis       Date:  2010-12       Impact factor: 4.915

5.  Identifying Structural Determinants of Product Specificity in Leishmania major Farnesyl Diphosphate Synthase.

Authors:  Sweta Maheshwari; Yu Seon Kim; Srinivas Aripirala; Michael Murphy; L Mario Amzel; Sandra B Gabelli
Journal:  Biochemistry       Date:  2020-07-12       Impact factor: 3.162

6.  Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.

Authors:  Marion Recher; Alejandro P Barboza; Zhu-Hong Li; Melina Galizzi; Mariana Ferrer-Casal; Sergio H Szajnman; Roberto Docampo; Silvia N J Moreno; Juan B Rodriguez
Journal:  Eur J Med Chem       Date:  2012-12-20       Impact factor: 6.514

7.  Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates.

Authors:  Srinivas Aripirala; Dolores Gonzalez-Pacanowska; Eric Oldfield; Marcel Kaiser; L Mario Amzel; Sandra B Gabelli
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-02-22

8.  New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.

Authors:  Mariana Ferrer-Casal; Catherine Li; Melina Galizzi; Carlos A Stortz; Sergio H Szajnman; Roberto Docampo; Silvia N J Moreno; Juan B Rodriguez
Journal:  Bioorg Med Chem       Date:  2013-11-13       Impact factor: 3.641

9.  Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design.

Authors:  Jacob D Durrant; Rong Cao; Alemayehu A Gorfe; Wei Zhu; Jikun Li; Anna Sankovsky; Eric Oldfield; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2011-08-03       Impact factor: 2.817

10.  Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa.

Authors:  Jason W Schmidberger; Robert Schnell; Gunter Schneider
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2015-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.